Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002118 · ClinicalTrials.gov registry record · NA
Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
A NA study, sponsored by University of Iowa.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01002118 is a NA study that was terminated before completion, run by University of Iowa. The registered enrollment target is 1 participants.
The verdict
NCT01002118, a NA study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent United States Renal Data System (USRDS), 40% of incident dialysis patients will have a cardiovascular event or die within the first 9 months of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3 fatty acid doses on cardiovascular parameters in an incident hemodialysis population. Initially, this will be a pilot study. Ultimately, the information will be used to adequately plan for a larger intervention trial using Omega-3 fatty acids in incident hemodialysis patients.
Interventions
- DRUG Placebo
- DRUG Omega-3 Acid Ethyl Esters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-01-25 |
| Est. Completion | 2011-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002118
The ClinicalTrials.gov registry entry for NCT01002118 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01002118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002118 about?
NCT01002118 is a clinical study titled "Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients". Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent United States Renal Data System (USRDS), 40% of incident dialysis patients will have a ca...
What is the current status of trial NCT01002118?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2008-01-25. Estimated completion is 2011-02-23.
What interventions are being tested in trial NCT01002118?
The interventions under investigation include: Placebo (DRUG), Omega-3 Acid Ethyl Esters (DRUG).
Who is sponsoring clinical trial NCT01002118?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.